恶性肿瘤脑膜转移发生机制及治疗研究进展
Research Progress on the Mechanism of Occurrence and Treatment of Leptomeningeal Metastasis of Malignant Tumors
DOI: 10.12677/acm.2024.1482230, PDF,    科研立项经费支持
作者: 闫晓乐*, 李学丰:内蒙古医科大学第一临床医学院,内蒙古 呼和浩特;王宏伟#:内蒙古医科大学附属医院放疗科,内蒙古 呼和浩特
关键词: 脑膜转移发病机制治疗Leptomeningeal Metastases Pathogenesis Treatment
摘要: 脑膜转移(Leptomeningeal metastasis, LM)是多种恶性肿瘤相对罕见却最严重最具挑战性的并发症,致死率极高。通常癌细胞可通过直接侵犯、血行播散、神经内、神经轴位及血管周围扩散、淋巴系统转移等途径浸润脑膜进入脑脊液(Cerebrospinal fluid, CSF)。CSF微环境处于缺氧及无细胞状态,仅含少量中间代谢产物及微量元素,癌细胞进入CSF后需要克服CSF微环境的限制并且躲避免疫反应。也有学者发现LM患者的CSF中补体C3 (Complement Component 3, C3)升高,可进一步提高血脑屏障通透性。对CSF中ctDNA进行检测可帮助了解肿瘤的基因突变特征、LM的发生发展机制及确定新的治疗靶点。目前LM转移的治疗方法有:鞘内化疗、放射治疗、靶向治疗及免疫治疗。通过对其机制的研究,后续针对LM治疗方案的制定是十分有益的。本文主要针对LM可能的发生机制及目前最新的相关治疗进展进行综述。
Abstract: Leptomeningeal metastasis (LM) is a relatively rare but the most serious and challenging complication of many malignant tumors, with an extremely high lethality rate. Cancer cells usually enter the CSF by infiltrating the leptomeninges through direct invasion, hematogenous dissemination, intra-neural, neuraxial and perivascular spread, and lymphatic metastasis, etc. The microenvironment of the CSF is hypoxic and acellular, and contains only a small amount of intermediary metabolites and micronutrients, so that the cancer cells need to overcome the limitations of the CSF microenvironment and avoid immune responses after entering the CSF. Some scholars have also found that C3 is elevated in the CSF of LM patients, which can further increase the permeability of the blood-brain barrier. Detection of ctDNA in CSF can help to understand the gene mutation characteristics of the tumor, the mechanism of LM development and identify new therapeutic targets. Current treatments for LM metastasis include intrathecal chemotherapy, radiation therapy, targeted therapy and immunotherapy. The subsequent development of therapeutic regimens for LM is beneficial through the study of its mechanisms. In this article, we summarize the possible mechanisms of LM and the latest therapeutic advances.
文章引用:闫晓乐, 王宏伟, 李学丰. 恶性肿瘤脑膜转移发生机制及治疗研究进展[J]. 临床医学进展, 2024, 14(8): 407-415. https://doi.org/10.12677/acm.2024.1482230

参考文献

[1] 谢雨文, 方和慧, 程弯弯, 等. EGFR突变型非小细胞肺癌软脑膜转移研究进展[J]. 临床肺科杂志, 2024, 29(5): 764-770.
[2] Wang, N., Bertalan, M.S. and Brastianos, P.K. (2017) Leptomeningeal Metastasis from Systemic Cancer: Review and Update on Management. Cancer, 124, 21-35. [Google Scholar] [CrossRef] [PubMed]
[3] Barbour, A.B., Kotecha, R., Lazarev, S., Palmer, J.D., Robinson, T., Yerramilli, D., et al. (2024) Radiation Therapy in the Management of Leptomeningeal Disease from Solid Tumors. Advances in Radiation Oncology, 9, Article ID; 101377. [Google Scholar] [CrossRef] [PubMed]
[4] Chamberlain, M., Le Rhun, E. and Taillibert, S. (2013) Carcinomatous Meningitis: Leptomeningeal Metastases in Solid Tumors. Surgical Neurology International, 4, S265-S288. [Google Scholar] [CrossRef] [PubMed]
[5] Le Rhun, E., Weller, M., van den Bent, M., Brandsma, D., Furtner, J., Rudà, R., et al. (2023) Leptomeningeal Metastasis from Solid Tumours: EANO-ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. ESMO Open, 8, Article ID: 101624. [Google Scholar] [CrossRef] [PubMed]
[6] Thakkar, J.P., Kumthekar, P., Dixit, K.S., Stupp, R. and Lukas, R.V. (2020) Leptomeningeal Metastasis from sOlid Tumors. Journal of the Neurological Sciences, 411, Article ID: 116706. [Google Scholar] [CrossRef] [PubMed]
[7] Spector, R., Robert Snodgrass, S. and Johanson, C.E. (2015) A Balanced View of the Cerebrospinal Fluid Composition and Functions: Focus on Adult Humans. Experimental Neurology, 273, 57-68. [Google Scholar] [CrossRef] [PubMed]
[8] Dankner, M., Lam, S., Degenhard, T., Garzia, L., Guiot, M., Petrecca, K., et al. (2021) The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. Cancers, 13, Article 732. [Google Scholar] [CrossRef] [PubMed]
[9] Chi, Y., Remsik, J., Kiseliovas, V., Derderian, C., Sener, U., Alghader, M., et al. (2020) Cancer Cells Deploy Lipocalin-2 to Collect Limiting Iron in Leptomeningeal Metastasis. Science, 369, 276-282. [Google Scholar] [CrossRef] [PubMed]
[10] Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., et al. (2004) IL-6 Mediates Hypoferremia of Inflammation by Inducing the Synthesis of the Iron Regulatory Hormone Hepcidin. Journal of Clinical Investigation, 113, 1271-1276. [Google Scholar] [CrossRef] [PubMed]
[11] Lin, X., Fleisher, M., Rosenblum, M., Lin, O., Boire, A., Briggs, S., et al. (2017) Cerebrospinal Fluid Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors. Neuro-Oncology, 19, 1248-1254. [Google Scholar] [CrossRef] [PubMed]
[12] Remsik, J., Chi, Y., Tong, X., Sener, U., Derderian, C., Park, A., et al. (2020) Leptomeningeal Metastatic Cells Adopt Two Phenotypic States. Cancer Reports, 5, e1236. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, P., Ma, Y., Wei, S. and Liang, X. (2021) The Dual Role of Complement in Cancers, from Destroying Tumors to Promoting Tumor Development. Cytokine, 143, Article ID: 155522. [Google Scholar] [CrossRef] [PubMed]
[14] Reis, E.S., Mastellos, D.C., Ricklin, D., Mantovani, A. and Lambris, J.D. (2017) Complement in Cancer: Untangling an Intricate Relationship. Nature Reviews Immunology, 18, 5-18. [Google Scholar] [CrossRef] [PubMed]
[15] Shalapour, S. and Karin, M. (2015) Immunity, Inflammation, and Cancer: An Eternal Fight between Good and Evil. Journal of Clinical Investigation, 125, 3347-3355. [Google Scholar] [CrossRef] [PubMed]
[16] Boire, A., Zou, Y., Shieh, J., Macalinao, D.G., Pentsova, E. and Massagué, J. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell, 168, 1101-1113.E13. [Google Scholar] [CrossRef] [PubMed]
[17] Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., et al. (2019) How Liquid Biopsies Can Change Clinical Practice in Oncology. Annals of Oncology, 30, 1580-1590. [Google Scholar] [CrossRef] [PubMed]
[18] Bettegowda, C., Sausen, M., Leary, R.J., et al. (2014) Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies. Science Translational Medicine, 6, 224ra24.
[19] Zhang, K., Dai, Z., Liu, S., et al. (2020) [Clinical Value of Cerebrospinal Fluid ctDNA in Patients with Non-Small Cell Lung Cancer Meningeal Metastasis]. Chinese Journal of Lung Cancer, 23, 1039-1048.
[20] Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., et al. (2018) Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer. Clinical Cancer Research, 24, 209-216. [Google Scholar] [CrossRef] [PubMed]
[21] Li, Y., Jiang, B., Yang, J., Tu, H., Zhou, Q., Guo, W., et al. (2016) Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. Journal of Thoracic Oncology, 11, 1962-1969. [Google Scholar] [CrossRef] [PubMed]
[22] 李琦, 徐玉秀, 邢海霞. 甲氨喋呤鞘内注射 + 全脑放疗治疗脑膜转移癌疗效观察[J]. 中国实用神经疾病杂志, 2016, 19(20): 113-114.
[23] Lukas, R.V., Thakkar, J.P., Cristofanilli, M., Chandra, S., Sosman, J.A., Patel, J.D., et al. (2022) Leptomeningeal Metastases: The Future Is Now. Journal of Neuro-Oncology, 156, 443-452. [Google Scholar] [CrossRef] [PubMed]
[24] Meng, Z., Zhang, Q., Hong, K., Han, W., Zhao, Z., Liu, Y., et al. (2018) Clinical Outcome and Prognostic Analysis of Meningeal Carcinomatosis Treated by Intrathecal Chemotherapy. Expert Review of Pharmacoeconomics & Outcomes Research, 18, 455-460. [Google Scholar] [CrossRef] [PubMed]
[25] Li, M., Zhang, Q., Fu, P., Li, P., Peng, A., Zhang, G., et al. (2012) Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. PLOS ONE, 7, e37229. [Google Scholar] [CrossRef] [PubMed]
[26] Fan, C., Zhao, Q., Li, L., Shen, W., Du, Y., Teng, C., et al. (2021) Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases from EGFR-Mutant NSCLC—A Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). Journal of Thoracic Oncology, 16, 1359-1368. [Google Scholar] [CrossRef] [PubMed]
[27] Bokstein, F., Lossos, A. and Siegal, T. (1998) Leptomeningeal Metastases from Solid Tumors: A Comparison of Two Prospective Series Treated with and without Intra-Cerebrospinal Fluid Chemotherapy. Cancer, 82, 1756-1763. [Google Scholar] [CrossRef
[28] El Shafie, R.A., Böhm, K., Weber, D., Lang, K., Schlaich, F., Adeberg, S., et al. (2019) Palliative Radiotherapy for Leptomeningeal Carcinomatosis–analysis of Outcome, Prognostic Factors, and Symptom Response. Frontiers in Oncology, 8, Article 641. [Google Scholar] [CrossRef] [PubMed]
[29] Yang, J.T., Wijetunga, N.A., Pentsova, E., Wolden, S., Young, R.J., Correa, D., et al. (2022) Randomized Phase II Trial of Proton Craniospinal Irradiation versus Photon Involved-Field Radiotherapy for Patients with Solid Tumor Leptomeningeal Metastasis. Journal of Clinical Oncology, 40, 3858-3867. [Google Scholar] [CrossRef] [PubMed]
[30] Hirano, Y., Konishi, K. and Ejima, Y. (2020) Utility of Whole Brain Radiation Therapy for Leptomeningeal Carcinomatosis. International Journal of Clinical Oncology, 25, 1432-1439. [Google Scholar] [CrossRef] [PubMed]
[31] Buszek, S.M. and Chung, C. (2019) Radiotherapy in Leptomeningeal Disease: A Systematic Review of Randomized and Non-Randomized Trials. Frontiers in Oncology, 9, Article 1224. [Google Scholar] [CrossRef] [PubMed]
[32] Yan, W., Liu, Y., Li, J., Han, A., Kong, L., Yu, J., et al. (2019) Whole Brain Radiation Therapy Does Not Improve the Overall Survival of EGFR-Mutant NSCLC Patients with Leptomeningeal Metastasis. Radiation Oncology, 14, Article No. 168. [Google Scholar] [CrossRef] [PubMed]
[33] Ahn, M., Chiu, C., Cheng, Y., Han, J., Goldberg, S.B., Greystoke, A., et al. (2020) Osimertinib for Patients with Leptomeningeal Metastases Associated with EGFR T790m-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. Journal of Thoracic Oncology, 15, 637-648. [Google Scholar] [CrossRef] [PubMed]
[34] Ahn, H.K., Han, B., Lee, S.J., Lim, T., Sun, J., Ahn, J.S., et al. (2012) ALK Inhibitor Crizotinib Combined with Intrathecal Methotrexate Treatment for Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis. Lung Cancer, 76, 253-254. [Google Scholar] [CrossRef] [PubMed]
[35] Dudnik, E., Siegal, T., Zach, L., Allen, A.M., Flex, D., Yust-Katz, S., et al. (2016) Durable Brain Response with Pulse-Dose Crizotinib and Ceritinib in ALK-Positive Non-Small Cell Lung Cancer Compared with Brain Radiotherapy. Journal of Clinical Neuroscience, 26, 46-49. [Google Scholar] [CrossRef] [PubMed]
[36] Bauer, T.M., Shaw, A.T., Johnson, M.L., Navarro, A., Gainor, J.F., Thurm, H., et al. (2020) Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Targeted Oncology, 15, 55-65. [Google Scholar] [CrossRef] [PubMed]
[37] Sun, M., Kim, I., Kim, Y., Jung, T., Moon, K., Jung, S., et al. (2021) Lorlatinib Therapy for Rapid and Dramatic Control of Brain and Spinal Leptomeningeal Metastases from ALK-Positive Lung Adenocarcinoma. Brain Tumor Research and Treatment, 9, 100-105. [Google Scholar] [CrossRef] [PubMed]
[38] Puri, S., Chaudhry, A., Bayable, A., Ganesh, A., Daher, A., Gadi, V.K., et al. (2023) Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients. Current Oncology Reports, 25, 1419-1430. [Google Scholar] [CrossRef] [PubMed]
[39] Kumthekar, P.U., Avram, M.J., Lassman, A.B., Lin, N.U., Lee, E., Grimm, S.A., et al. (2022) A Phase I/II Study of Intrathecal Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive (HER2-Positive) Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics. Neuro-Oncology, 25, 557-565. [Google Scholar] [CrossRef] [PubMed]
[40] Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B. and Boogerd, W. (2016) Targeted Treatment and Immunotherapy in Leptomeningeal Metastases from Melanoma. Annals of Oncology, 27, 1138-1142. [Google Scholar] [CrossRef] [PubMed]
[41] Mittapalli, R.K., Vaidhyanathan, S., Dudek, A.Z. and Elmquist, W.F. (2012) Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RAFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics, 344, 655-664. [Google Scholar] [CrossRef] [PubMed]
[42] Khosla, A.A., Saxena, S., Ozair, A., Venur, V.A., Peereboom, D.M. and Ahluwalia, M.S. (2022) Novel Therapeutic Approaches in Neoplastic Meningitis. Cancers, 15, Article 119. [Google Scholar] [CrossRef] [PubMed]
[43] Barden, M.M. and Omuro, A.M. (2023) Top Advances of the Year: Neuro‐Oncology. Cancer, 129, 1467-1472. [Google Scholar] [CrossRef] [PubMed]
[44] Glitza, I.C., Rohlfs, M., Guha-Thakurta, N., Bassett, R.L., Bernatchez, C., Diab, A., et al. (2018) Retrospective Review of Metastatic Melanoma Patients with Leptomeningeal Disease Treated with Intrathecal Interleukin-2. ESMO Open, 3, e000283. [Google Scholar] [CrossRef] [PubMed]
[45] Bhambhvani, H.P., Rodrigues, A.J., Umeh-Garcia, M.C. and Hayden Gephart, M. (2020) Leptomeningeal Carcinomatosis: Molecular Landscape, Current Management, and Emerging Therapies. Neurosurgery Clinics of North America, 31, 613-625. [Google Scholar] [CrossRef] [PubMed]